Lee Dong-hoon, CEO of SK Biopharm, stated during his New Year's address on the 2nd, "We will respond to compressed and rapid changes based on a strong yet flexible organization."
He noted, "I was able to clearly feel our achievements and status while going overseas," and added, "When I attended global events like last year's Bio USA and the American Epilepsy Society, I could distinctly confirm SK Biopharm's presence." He emphasized, "Such experiences became an opportunity to reflect on our achievements and vision, and to redefine the direction we need to take moving forward."
He also remarked, "The year 2025 will be a year to consolidate the changes and challenges of the past few years into a greater and bolder leap," adding, "The speed and depth of change will pose greater challenges for us, but we must achieve the fundamental goal of innovative drug development and improving patients' quality of life through optimal decisions."
He identified the biggest topic for 2025 as being the year of the globalization of "research and development." He expressed aspirations to systematically reorganize the global research and development network connecting Korea, the United States, Asia, and Europe, and to focus on equipping the highest level of research capabilities. He also emphasized that this process of globalization is a gateway that must be passed through on the path to becoming a global large-scale biotech company.
He pledged, "Looking back later, I believe we can say that 2025 was the turning point for our leap into a global company."